These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 12720157

  • 1. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR.
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [Abstract] [Full Text] [Related]

  • 2. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ, Gillum AM, Klem RE, Frankel SR.
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [Abstract] [Full Text] [Related]

  • 3. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
    Herbst RS, Frankel SR.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
    [Abstract] [Full Text] [Related]

  • 4. Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides.
    Nichols GL, Stein CA.
    Semin Oncol; 2003 Apr 15; 30(2):297-9. PubMed ID: 12720156
    [Abstract] [Full Text] [Related]

  • 5. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD.
    Oncology (Williston Park); 2004 Nov 15; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [Abstract] [Full Text] [Related]

  • 6. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007 Nov 15; 8(5):321-34. PubMed ID: 17767397
    [Abstract] [Full Text] [Related]

  • 7. Bcl-2 antisense therapy in B-cell malignancies.
    Chanan-Khan A.
    Blood Rev; 2005 Jul 15; 19(4):213-21. PubMed ID: 15784299
    [Abstract] [Full Text] [Related]

  • 8. [Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results].
    Büchele T.
    Onkologie; 2003 Dec 15; 26 Suppl 7():60-9. PubMed ID: 14716145
    [Abstract] [Full Text] [Related]

  • 9. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.
    Moreira JN, Santos A, Simões S.
    Rev Recent Clin Trials; 2006 Sep 15; 1(3):217-35. PubMed ID: 18473975
    [Abstract] [Full Text] [Related]

  • 10. Genasense (Genta Inc).
    Banerjee D.
    Curr Opin Investig Drugs; 2001 Apr 15; 2(4):574-80. PubMed ID: 11566020
    [Abstract] [Full Text] [Related]

  • 11. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB.
    Clin Cancer Res; 2004 Nov 15; 10(22):7662-70. PubMed ID: 15569999
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
    Kim R, Emi M, Tanabe K, Toge T.
    Cancer; 2004 Dec 01; 101(11):2491-502. PubMed ID: 15503311
    [Abstract] [Full Text] [Related]

  • 13. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
    Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS.
    Br J Haematol; 2004 Dec 01; 127(5):519-30. PubMed ID: 15566355
    [Abstract] [Full Text] [Related]

  • 14. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K.
    Clin Cancer Res; 2003 Sep 15; 9(11):4267-73. PubMed ID: 14519654
    [Abstract] [Full Text] [Related]

  • 15. Oblimersen in the treatment of metastatic melanoma.
    Tarhini AA, Kirkwood JM.
    Future Oncol; 2007 Jun 15; 3(3):263-71. PubMed ID: 17547520
    [Abstract] [Full Text] [Related]

  • 16. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
    Kim R, Emi M, Matsuura K, Tanabe K.
    Cancer Gene Ther; 2007 Jan 15; 14(1):1-11. PubMed ID: 17041564
    [Abstract] [Full Text] [Related]

  • 17. Bcl-2 antisense therapy in multiple myeloma.
    Chanan-Khan AA.
    Oncology (Williston Park); 2004 Nov 15; 18(13 Suppl 10):21-4. PubMed ID: 15651173
    [Abstract] [Full Text] [Related]

  • 18. Potential therapeutic applications of oblimersen in CLL.
    Koziner B.
    Oncology (Williston Park); 2004 Nov 15; 18(13 Suppl 10):32-8. PubMed ID: 15651175
    [Abstract] [Full Text] [Related]

  • 19. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May 15; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 20. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
    van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM.
    Leukemia; 2003 Jan 15; 17(1):211-9. PubMed ID: 12529680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.